Literature DB >> 23341792

Poorly differentiated neuroendocrine carcinoma in a perigastric lymph node from an unknown primary site.

Hee Seung Lee1, Hye-Suk Han, Sung-Nam Lim, Hyun-Jung Jeon, Ho-Chang Lee, Ok-Jun Lee, Hyo Young Yun, Ki Hyeong Lee, Seung Taik Kim.   

Abstract

Neuroendocrine carcinomas from an unknown primary site are uncommon. The authors report on a case of neuroendocrine carcinoma in a perigastric lymph node (LN) with no primary site. A 52-year-old male patient with early gastric adenocarcinoma underwent treatment by endoscopic submucosal dissection, and, six months later, findings on a computed tomographic scan of the abdomen revealed a LN enlargement measuring 2.0 cm in the perigastric region. The patient underwent subtotal gastrectomy and regional LN dissection under a suggestive preoperative diagnosis of gastric adenocarcinoma with LN metastasis. However, microscopically, no residual tumor was found in the stomach, and the perigastric LN showed poorly differentiated neuroendocrine carcinoma (PDNEC). After an extensive workup, no primary site was identified. The patient also received four cycles of etoposide and cisplatin. Despite its extremely rare incidence, this case suggests that PDNEC of an unknown primary site is limited to a single site, and that resection should be considered in combination with chemotherapy.

Entities:  

Keywords:  Lymph nodes; Neuroendocrine carcinoma; Unknown primary neoplasms

Year:  2012        PMID: 23341792      PMCID: PMC3546275          DOI: 10.4143/crt.2012.44.4.271

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  10 in total

1.  Nodal neuroendocrine (Merkel cell) carcinoma without an identifiable primary tumor.

Authors:  Hiroko Kuwabara; Hiroshi Mori; Hirotsugu Uda; Kiyozumi Takei; Yoshichika Ishibashi; Naotomo Takatani
Journal:  Acta Cytol       Date:  2003 May-Jun       Impact factor: 2.319

2.  Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.

Authors:  John D Hainsworth; David R Spigel; Sharlene Litchy; F Anthony Greco
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

3.  Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?

Authors:  E Bajetta; L Catena; G Procopio; E Bichisao; L Ferrari; S Della Torre; S De Dosso; S Iacobelli; R Buzzoni; L Mariani; J Rosai
Journal:  Ann Oncol       Date:  2005-06-06       Impact factor: 32.976

4.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Authors:  M L Fjällskog; D P Granberg; S L Welin; C Eriksson; K E Oberg; E T Janson; B K Eriksson
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

5.  [Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma].

Authors:  Junji Ueda; Takayuki Aimoto; Yoshiharu Nakamura; Makoto Hiroi; Kazuya Yamahatsu; Tomohiro Hayakawa; Zenya Naito; Eiji Uchida
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2010-12

6.  A case of long-term recurrence-free poorly differentiated neuroendocrine carcinoma of lymph nodes treated by surgical resection without any chemotherapy.

Authors:  Shigeo Hisamori; Hiroshi Okabe; Akihiko Yoshizawa; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2010-03-12       Impact factor: 3.402

7.  Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.

Authors:  J D Hainsworth; D H Johnson; F A Greco
Journal:  Ann Intern Med       Date:  1988-09-01       Impact factor: 25.391

Review 8.  Neuroendocrine carcinoma of unknown primary site.

Authors:  David R Spigel; John D Hainsworth; F Anthony Greco
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

9.  Neuroendocrine (Merkel cell) carcinoma of the retroperitoneum with no identifiable primary site.

Authors:  Van Boghossian; Ira D Owen; Balakrishna Nuli; Philip Q Xiao
Journal:  World J Surg Oncol       Date:  2007-10-19       Impact factor: 2.754

10.  Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

Authors:  E Mitry; E Baudin; M Ducreux; J C Sabourin; P Rufié; T Aparicio; T Aparicio; P Lasser; D Elias; P Duvillard; M Schlumberger; P Rougier
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  10 in total
  2 in total

1.  Submucosal small-cell neuroendocrine carcinoma of the larynx detected using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report and review of the literature.

Authors:  Hong-Fang Ying; Yang-Yang Bao; Shui-Hong Zhou; Liang Chai; Kui Zhao; Ting-Ting Wu
Journal:  Oncol Lett       Date:  2014-06-12       Impact factor: 2.967

2.  Synchronous Gastric Adenocarcinoma and Perigastric Lymph Node Metastatic Squamous Cell Carcinoma with Unknown Primary: A Case Report.

Authors:  Bernard K Seshie; Ki Hyun Kim; Hyun Jung Lee; Si Hak Lee; Sun-Hwi Hwang
Journal:  J Minim Invasive Surg       Date:  2020-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.